Results 161 to 170 of about 3,035 (215)

Cancer Patient Perspectives on Clinical Trial Discussion and Informed Consent Through Telemedicine. [PDF]

JCO Oncol Pract
Khadem Charvadeh Y, Doshi SD, Seier K, Bange EM, Daly B, Lipitz-Snyderman A, Polubriaginof FCG, Buckley M, Kuperman G, Stetson PD, Schrag D, Morris MJ, Panageas KS.   +12 more
europepmc   +1 more source

Leveraging natural language processing to aggregate field safety notices of medical devices across the EU. [PDF]

NPJ Digit Med
Ren Y, Caiani EG.
europepmc   +1 more source

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. [PDF]

Cancer
Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM.   +17 more
europepmc   +1 more source

A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma. [PDF]

Cancers (Basel)
Steiner C, Han T, Safi S, Bzeih W, Mansour H, Saad E, Williams JF, Hirsch MS, Giri VK, Ascione L, Elon Y, Dicker AP, Tang Y, Choueiri TK, Henske EP, Xu W.   +15 more
europepmc   +1 more source

Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer. [PDF]

Clin Lung Cancer
Sun F, Nagpal S, Singhal S, Neal JW, Wakelee HA, Myall NJ, Bolan P, Riess JW, Gandara DR, Das MS.   +9 more
europepmc   +1 more source

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer. [PDF]

Clin Cancer Res
Yang DD, Abdelnaser A, Haas AJ, Wala J, Barney AA, Saad E, Crowdis JP, Ricker CA, Awad S, Gurel B, Park J, King MT, Nguyen PL, Choueiri TK, Einstein DJ, Balk SP, Tewari AK, de Bono JS, Salari K, Taplin ME, Wu CL, Van Allen EM.   +21 more
europepmc   +1 more source

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma. [PDF]

Blood Cancer J
Jurgens E, Shekarkhand T, Rueda C, Nemirovsky D, Derkach A, Firestone RS, Miller K, Costa BA, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Hamadeh I, Giralt SA, Shah GL, Landau HJ, Scordo M, Usmani SZ, Mailankody S, Shahid Z.   +24 more
europepmc   +1 more source

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. [PDF]

Blood Adv
Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque TZ, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss IT, Stein EM.   +16 more
europepmc   +1 more source

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. [PDF]

Oncologist
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O.   +34 more
europepmc   +1 more source

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma. [PDF]

Int J Clin Oncol
Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T.   +19 more
europepmc   +1 more source